Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of a neurodegenerative disease selected from the group consisting of a-synucleinopathy, in particular Lewy body disease, Huntington's disease, frontotemporal neurocognitive disorder, and amyotrophic lateral sclerosis in an individual.

Abstract: A method for aggregating and regulating messages in a network that has a plurality of pairs of nodes and two transmitting/receiving devices communicating via a bidirectional channel. The method is implemented by each of the transmitting/receiving devices. Each received message may be segmented into packets of a predefined size, and each packet may be allocated to a queue that depends on the origin, the destination, and the priority of the message. One or more frames may then be created, and packets of the queues may be inserted into the frames. Frames may then be sent via the bidirectional channel over a predefined time interval, the number of frames sent over the time interval being dependent on the maximum throughput of the channel and on the useful throughput in each of the transport directions of the channel.

Abstract: A method for aggregating and regulating messages in a network that has a plurality of pairs of nodes and two transmitting/receiving devices communicating via a bidirectional channel. The method is implemented by each of the transmitting/receiving devices. Each received message may be segmented into packets of a predefined size, and each packet may be allocated to a queue that depends on the origin, the destination, and the priority of the message. One or more frames may then be created, and packets of the queues may be inserted into the frames. Frames may then be sent via the bidirectional channel over a predefined time interval, the number of frames sent over the time interval being dependent on the maximum throughput of the channel and on the useful throughput in each of the transport directions of the channel.

Abstract: A limb stabilizing device includes a base, a first clamping member adjustably mounted to the base, and a second clamping member mounted in an opposed relationship with the first clamping member. The first clamping member includes a first adjustment mechanism that operates to allow the first clamping member to slide laterally along the base and to maintain the first and second clamping members in lateral alignment.

Abstract: Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1 to 2, morphine to oxycodone by weight.

Abstract: A limb stabilizing device includes a base, a first clamping member adjustably mounted to the base, and a second clamping member mounted in an opposed relationship with the first clamping member. The first clamping member includes a first adjustment mechanism that operates to allow the first clamping member to slide laterally along the base and to maintain the first and second clamping members in lateral alignment.

Abstract: A fluid applicator system includes a container member that has a bottom wall and a perimeter wall that extend upwardly from the bottom wall. The bottom wall and the perimeter wall define an interior space. The container member has top portion coupled to the perimeter wall. The top portion has an aperture that extends therethrough. The container member is for storing a fluid to be applied. An extension member is substantially hollow and elongate. The extension member has an interior in environmental communication with the interior space of the container member. An applicator assembly is operationally coupled to the extension member such that fluid stored in the container member is flowable through the extension member to an exterior surface of the applicator assembly, the applicator assembly is for applying the fluid to skin of a user.

Abstract: Patients' limb immobilizers for stabilizing fractured or broken limbs, which may be enclosed in casts, are structured to eliminate rolling movement of the limb, to promote comfort and healing. Laterally extending support bases resting on a bed or other underlying support surface are provided with a pair of upwardly-extending limb-embracing elements, which are adjustable to provide close embrace of the patient's limb. The elements may be rigid or flexible; they are releasably clamped on the patient's limb for optimum immobilization.

Abstract: A limb positioning and stabilizing device provides, in a unitary construction, an arcuate limb engaging element, which, when forced open, will return to its original shape when the force is no longer applied, for embracing an injured limb, and also provides a wide transverse support base, which is integral with the limb engaging element, for bracing the limb engaging element when the device is in operation. The device further provides a padded inner lining for protecting the injured limb and an attachment means for attaching a plurality of the devices in parallel for use with longer limbs.

Abstract: A selective collector of a human patient's saliva for monitoring or analysis is formed as a substantially conical flat concave cup of resilient molded polymer with tubing connections at an apex portal, and a large entrance portal having a soft compliant foam elastomer rim positioned for contact with the patient's soft tissue, such as the interior of the patient's cheek around the parotid salivary duct.Suction is connected to the soft foam rim, holding the concave cup in position, and suction, fixed pressure, pulsing pressure or electrical stimulation may promote the flow of saliva to a collector vessel. Medication may be administered to the patient's soft tissue if desired throug the entrance portal.

Abstract: A method of screening for sickle cell disease is provided by detecting the presence of porphyrins and porphyrin metabolites in human teeth comprising cleaning the teeth, exposing the cleaned teeth in vivo to a source of light, which has a wavelength known to excite the fluorescent emission spectrum characteristic of porphyrins and porphyrin metabolites and, optimally, which emits a wavelength of about 360 nm, detecting fluorescence, either visually or photographically, and determining the presence of porphyrins or porphyrin metabolites by emission of fluorescence characteristic thereto.